chimeric antigen receptor T-cell therapy + galectin-3 inhibitor

This therapeutic approach involves chimeric antigen receptor (CAR) T cells engineered to locally secrete a protein-based inhibitor of Galectin-3 (Gal3). Developed to overcome the immunosuppressive tumor microenvironment (TME) in pediatric solid tumors, the therapy targets Gal3, a carbohydrate-binding protein predominantly expressed by M2-like macrophages that correlates with reduced T-cell infiltration and activation. By neutralizing Gal3 within the TME, these "armed" CAR T cells aim to reprogram myeloid-driven suppression, thereby improving T-cell infiltration and enhancing the overall anti-tumor efficacy and durability of the CAR T-cell response in solid malignancies.

Other names

Gal3-inhibitor secreting CAR T-cellsGal-3-inhibitor secreting CAR T-cellsGal 3-inhibitor secreting CAR T-cellsGal3-armed CAR T-cellsGal-3-armed CAR T-cellsGal 3-armed CAR T-cellsarmed CAR T cell (Gal3 inhibitor)